<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977012</url>
  </required_header>
  <id_info>
    <org_study_id>NOR17-KR-IIT</org_study_id>
    <nct_id>NCT03977012</nct_id>
  </id_info>
  <brief_title>Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients</brief_title>
  <official_title>Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome(CRPS) Patients With Chronic Lower Back Pain: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study, we aim to investigate the effect of buprenorphine on neuroinflammation
      in patients with complex regional pain syndrome, using [11C]-(R)-PK11195 PET.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in neuroinflammation</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>[11C]-(R)-PK11195 PET distribution volume ratio (DVR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine equivalent</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>narcotic analgesic dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical test(1)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical test(2)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>urine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical test(3)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Electrocardiogram(ECG) test (pulse rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical test(4)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>pulse measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical test(5)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported questionnaire(1)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Beck Depression Index(BDI)/ total score: 0~63, The higher the score, the more depressed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported questionnaire(2)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Beck Anxiety Index(BAI)/ total score: 0~63, The higher the score, the more anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported questionnaire(3)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Short Form McGill Pain Questionnaire(SF-MPQ)/ 'a' subscale score: 0~45, The higher the score, the more painful/ 'b' subscale score, 0~10, The higher the score, the more painful/ 'c' subscale score, 0~5, The higher the score, the more painful</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported questionnaire(4)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Pain Catastrophizing Scale/ total score: 0~52, The higher the score, the more pain Catastrophizing</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Complex Regional Pain Syndromes</condition>
  <arm_group>
    <arm_group_label>Patients with CRPS Type I</arm_group_label>
    <description>Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care.
-drug name: norspan patch 5~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>5~20 mcg</description>
    <arm_group_label>Patients with CRPS Type I</arm_group_label>
    <other_name>norspan patch</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with complex regional pain syndrome Type I (Budapest Criteria)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with complex regional pain syndrome Type I (Budapest Criteria) and
             persistent back pain (VAS â‰¥ 4).

          2. Patients who can stop benzodiazepine treatment 2 weeks before study

          3. Patients who initially decided to use buprenorphine according to clinical judgment

          4. Patients who are able to understand the purpose and procedure of the study

        Exclusion Criteria:

          1. Patients with an impaired cognitive function such as psychosis, dementia, or mental
             retardation

          2. Patients with neurologic disease, cerebrovascular disease, history of brain tumor,
             history of severe head trauma, history of convulsive disease

          3. Patients with cardiovascular disease, liver, respiratory or renal dysfunction

          4. Patients with biliary disease

          5. Patients who could not undergo the PET/magnetic resonance imaging (MRI) process.

          6. Patients who have a risk of suicide or show aggressive behavior

          7. Patients who have drug dependence (DSM-IV criteria) or history (past 6 months or
             older)

          8. Employees of researchers or clinical research institutes

          9. Patients with hypersensitivity or contraindication to buprenorphine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soo-Hee Choi, MD,PhD</last_name>
    <phone>+82 2-2072-2302</phone>
    <email>soohchoi@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo-Hee Choi, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Hee Choi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

